(Q47305826)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22861496%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Safety and efficacy evaluation of ambrisentan in pulmonary hypertension (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22861496%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22861496%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Francesco Fedele

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22861496%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Beatrice Pezzuto

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22861496%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Lewis J Rubin

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22861496%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

English

0 references

publication date

4 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22861496%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Safety

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22861496%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22861496%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22861496%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

1003-1011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22861496%20AND%20SRC:MED&resulttype=core&format=json

Updated clinical classification of pulmonary hypertension.

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Cellular and molecular pathobiology of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Possible role of endothelin in endothelial regulation of vascular tone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Endothelin receptor antagonists in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Ambrisentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Bosentan for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Clinical pharmacology of bosentan, a dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Effect of ketoconazole on the pharmacokinetic profile of ambrisentan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Potential for pharmacokinetic interactions between ambrisentan and cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.714770